Jack Bendheim Sells 328 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 328 shares of Phibro Animal Health stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $40.09, for a total transaction of $13,149.52. Following the completion of the transaction, the chief executive officer owned 38,872 shares of the company’s stock, valued at $1,558,378.48. This represents a 0.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.77, for a total value of $143,510.40.
• On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $43.93, for a total value of $309,267.20.
• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.02, for a total value of $232,425.60.
• On Monday, November 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.56, for a total transaction of $235,276.80.
• On Thursday, November 13th, Jack Bendheim sold 8,801 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.47, for a total transaction of $391,380.47.
• On Wednesday, November 12th, Jack Bendheim sold 21,536 shares of Phibro Animal Health stock. The shares were sold at an average price of $45.23, for a total transaction of $974,073.28.
• On Monday, November 10th, Jack Bendheim sold 38,303 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.29, for a total transaction of $1,734,742.87.

Phibro Animal Health Price Performance

NASDAQ:PAHC traded up $0.29 during trading hours on Thursday, hitting $39.72. The stock had a trading volume of 153,681 shares, compared to its average volume of 196,536. The company has a 50 day simple moving average of $40.89 and a two-hundred day simple moving average of $36.40. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 23.93, a P/E/G ratio of 1.12 and a beta of 0.79. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35. Phibro Animal Health Corporation has a one year low of $16.16 and a one year high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The company had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Research analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s payout ratio is currently 28.92%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PAHC. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. JPMorgan Chase & Co. lifted their price target on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Phibro Animal Health currently has a consensus rating of “Hold” and a consensus target price of $31.40.

Institutional Trading of Phibro Animal Health

Several hedge funds and other institutional investors have recently bought and sold shares of PAHC. Capricorn Fund Managers Ltd bought a new position in Phibro Animal Health in the 3rd quarter worth $10,233,000. Kings Path Partners LLC increased its stake in shares of Phibro Animal Health by 87.3% during the second quarter. Kings Path Partners LLC now owns 20,600 shares of the company’s stock valued at $526,000 after purchasing an additional 9,600 shares in the last quarter. Voya Investment Management LLC lifted its holdings in shares of Phibro Animal Health by 44.3% during the first quarter. Voya Investment Management LLC now owns 31,894 shares of the company’s stock valued at $681,000 after purchasing an additional 9,796 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Phibro Animal Health during the third quarter valued at approximately $8,931,000. Finally, Bailard Inc. bought a new stake in shares of Phibro Animal Health in the 2nd quarter worth approximately $259,000. Institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.